EXHIBIT 99.1



            BD Acquires Right to Negotiate Business Relationship for
                Accelr8's BACcel(R) Rapid Diagnostics Technology

DENVER, Colo., December 13, 2007 - Accelr8 Technology Corporation (Amex:AXK)
announced today that that Becton Dickinson and Company (NYSE: BDX) purchased an
exclusive right on December 12, 2007 to negotiate for a business relationship to
develop Accelr8's BACcel(R) rapid diagnostic platform. The right grants to BD an
exclusive discussion period through March 31, 2008 during which the companies
will explore a possible product development relationship and definitive terms
for such a relationship. If agreement is reached, terms may include any of the
elements or combination of elements of licensing, equity investment, joint
development, or other mutually suitable product development and
commercialization program. BD will pay Accelr8 $100,000 for the right.

According to David Howson, Accelr8's president, "this agreement demonstrates
serious interest in our rapid diagnostic platform by a leader in the clinical
diagnostics market. BD recognizes the potential value of the BACcel system as a
`fast front end' that complements their automated culturing systems and gene
analysis products. The BACcel system uniquely addresses a critical need in
hospital ICUs that no other technology now addresses. We target hospital
acquired infections (HAI) and antibiotic resistance in pathogens that include
the worst multi-resistant so-called `superbugs' such as MRSA, Acinetobacter,
Pseudomonas, and emerging strains of Klebsiella and E. coli.

"With life-threatening infections, physicians need guidance for initial therapy
within a few hours of a patient's first presentation of symptoms. In the best of
cases, culturing requires at least a full day to produce results, and that is
too late to affect patient outcomes. The physician cannot wait that long to
begin therapy and must proceed without specific guidance. Because of widespread
and increasingly complex antibiotic resistance, approximately 20% to 40% of
attempts with initial therapy prove inadequate.

"The BACcel system has unique capabilities. It eliminates culturing delays by
using well-understood analytical principles in a novel strategy to analyze
bacteria extracted directly from a patient specimen. We have presented data to
the scientific and medical communities that support our objective of reporting
pathogen identity and quantity within two hours of specimen access, and major
antibiotic resistance mechanism identification within six hours. This will help
the physician to rule out antibiotics that are most likely to fail, leaving
those that are most likely to prove adequate. "The nature of this agreement
reflects BD's desire to quickly explore and define mutually beneficial ways to
seize this unique opportunity. BD could bring many resources to bear and speed
the path to market, helping to further consolidate their leadership in managing
infectious diseases," Howson concluded.








About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is
developing a rapid clinical pathogen diagnostic platform, the BACcel(R) system,
based on its innovative surface coatings, assay processing, and detection
technologies. In addition, Accelr8 licenses certain of its proprietary
technology for use in applications outside of Accelr8's own products.


- --------------------------------------------------------------------------------

    Certain statements in this news release may be "forward-looking
    statements" within the meaning of Section 27A of the Securities Act of
    1933, as amended, and Section 21E of the Securities Exchange Act of
    1934, as amended. Statements regarding future prospects and
    developments are based upon current expectations and involve certain
    risks and uncertainties that could cause actual results and
    developments to differ materially from the forward-looking statement,
    including those detailed in the company's filings with the Securities
    and Exchange Commission. Accelr8 does not undertake an obligation to
    publicly update or revise any forward-looking statements, whether as a
    result of new information or future events.

- --------------------------------------------------------------------------------



Contact
John Metzger, of Metzger Associates
+1.303.786.7000, ext. 2202
john@metzger.com

OR

Tom Geimer, of Accelr8 Technology Corp.
+1.303.863.8088
tom.geimer@accelr8.com


                                       ###